- Funding Round Led by Radical Ventures: Includes participation from AstraZeneca, Bristol Myers Squibb, and Takeda.
- AI and Wet-Lab Technologies: Focus on atomically precise drug design and high-throughput measurement of drug function.
- Expansion and Development: Funds to expand operations and enhance development efforts.
Impact
- Increased R&D Capabilities: Funding enables further development of AI and wet-lab technologies.
- Strategic Collaborations: Partnerships with major pharmaceutical companies enhance drug development pipelines.
- Advanced Drug Design: Focus on antibodies targeting multipass membrane proteins, improving treatment options.
- Sustainable Growth: Collaborations offset R&D expenses, promoting rapid and sustainable growth.
- Valuable Disease Insights: Partnerships provide deeper understanding of disease biology and platform development.
Eksentricity 
Leave a comment